|Bid||34.30 x 100|
|Ask||38.00 x 400|
|Day's Range||36.00 - 37.42|
|52 Week Range||21.90 - 37.42|
|PE Ratio (TTM)||18,625.00|
|Earnings Date||Nov 14, 2017 - Nov 20, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.10|
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will be attending two upcoming investor conferences in New York City.
Here take a quick look on three major MedTech companies that are going to make the best out of the recent Tax-Repeal upheaval.
On February 27, 2018, Abbott Laboratories (ABT) and Surmodics (SRDX) announced that the two companies have entered an agreement for the commercialization rights of Surmodics’ SurVeil DCB (drug-coated balloon) for the treatment of superficial femoral artery. As per the agreement, Abbott Laboratories will gain exclusive commercial rights for the SurVeil DCB, which is currently in clinical trials. Surmodics will supply the device to Abbott once approved.
Abbott (ABT) gains traction from its newly acquired rights over the SurVeil drug-coated balloon, which shows greater potential for capturing the market compared with traditional devices.
Med-tech firm Surmodics Inc. has landed a licensing deal with health care giant Abbott Laboratories Inc. that could be worth up to $92 million, the companies announced Tuesday. Eden Prairie-based Surmodics will exclusively license its SurVeil drug-coated balloon device to Abbott (ABT). Surmodics is testing the device as a treatment for peripheral artery disease.
- COMPANIES TO COLLABORATE ON PRODUCT DEVELOPMENT, CLINICAL TRIALS AND REGULATORY ACTIVITIES TO OBTAIN APPROVAL IN U.S. AND E.U. ABBOTT PARK, Ill. and EDEN PRAIRIE, Minn., Feb. 27, 2018 /PRNewswire/ -- Abbott (ABT) and Surmodics (SRDX) today announced that the companies have entered into an agreement whereby Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial.
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at 4:00 p.m. CT , as a virtual meeting.
The Eden Prairie, Minnesota-based company said it had a loss of 12 cents per share. Earnings, adjusted for pretax expenses and non-recurring costs, were 10 cents per share. The drug delivery technology ...
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 first quarter, ended December 31, 2017, and updated financial outlook for fiscal 2018.
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2018 conference call on Thursday, February 8, at 7:30 a.m.
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration 510 clearance for its Telemark™ .014” coronary and peripheral support microcatheter.
NEW YORK, Jan. 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Basic ...
Surmodics' (SRDX) top line benefits from strong sales in Medical Device and IVD businesses. However, foreign currency is a headwind.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for SurModics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Surmodics Inc (NASDAQ:SRDX) files its latest 10-K with SEC for the fiscal year ended on September 30, 2017.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives SurModics, Inc. a score of 67. Our analysis is based on comparing SurModics, Inc. with the following peers – Nektar Therapeutics, Thermo Fisher Scientific Inc., Heron Therapeutics Inc, Abbott Laboratories, pSivida Corp., Johnson & Johnson, PerkinElmer, Inc., Enzo Biochem, Inc., Alkermes Plc and Agilent Technologies, Inc. (NKTR-US, ... Read more (Read more...)
Based on the latest analyst prediction, Surmodics Inc (NASDAQ:SRDX) is estimated to immensely contract its earnings by beyond -150% next year. Presently, with an EPS of $0.298, we can expectRead More...
SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.